Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ · Manufacturing · Pharmaceutical preparations
$2.65−$0.0300 (−1.12%) on the dayAs of the close; data may be delayed.
ELDN price, last 12 months
Key stats
- Previous close
- $2.68
- Open
- $2.68
- Day range
- $2.62 – $2.69
- 52-week range
- $1.35 – $4.60
- Volume
- 620.1K
- Avg volume (20 days)
- 996.4K
- Market cap
- $215.3M
Performance
1W+1.2%
1M−20.9%
3M−29.9%
6M−10.5%
YTD+75.5%
1Y+9.5%
vs S&P 500, 1Y−7.3 pts
Technicals and fundamentals
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $215.3M